Views & Analysis R&D roundup: the ups and downs of CRISPR and Alzheimer’s While the controversy surrounding Vertex Pharma’s cystic fibrosis drug in the UK grows more intense, the US firm has announced that it is licensing back two gene editing compounds that can
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
